8 completed, 8 recruiting, 6 terminated, 5 active not recruiting. 29 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Completed 8, Recruiting 8, Terminated 6, Active not recruiting 5, Unknown 2 |
| Phase 2 | 10 | Terminated 4, Completed 3, Recruiting 2, Unknown 1 |
Follow SABR: new trials by email Literature Review of SABR trials Research Report on SABR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2026-09-01 | 2026-10-19 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer Biopsy, Biospecimen Collection, Bone Scan - Breast Carcinoma, Colorectal Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2025-05-27 | 2026-10-28 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy - Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | University of California, Davis | 24 | 2023-12-07 | 2026-03-12 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab - Metastatic Malignant Solid Neoplasm, Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2022-06-20 | 2026-10-30 |
| Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC Atezolizumab, Stereotactic Body Radiation Therapy - Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-04-19 | 2026-01-28 |
| Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Pleural Mesothelial Neoplasm | Phase 1 | Completed | Mayo Clinic | 20 | 2021-07-12 | 2026-07-08 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration - Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2020-03-18 | 2024-11-07 |
| Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy - Lung Non-Small Cell Carcinoma, Positive Surgical Margin | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 50 | 2019-12-04 | 2026-08-24 |
| Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg - Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 16 | 2019-09-11 | 2026-02-05 |
| BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab - Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 51 | 2019-08-19 | 2025-12-03 |
| PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer PD-1 inhibitor JS-001 - Extensive-stage Small Cell Lung Cancer, Radiotherapy | Phase 1 | Unknown | Chinese Academy of Medical Sciences | 6 | 2019-06-01 | 2019-06-04 |
| Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 19 | 2019-02-07 | 2026-10-16 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NBTXR3, SABR, Nivolumab - Radiotherapy, Immunotherapy | Phase 1 | Active not recruiting | Nanobiotix | 145 | 2019-01-16 | 2025-10-24 |
| Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Completed | University of Washington | 20 | 2019-01-15 | 2023-12-29 |
| Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 / Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 19 | 2018-10-04 | 2023-11-18 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Squamous Cell Carcinoma of Head and Neck (7) · Lung Neoplasms (5) · Oropharyngeal Neoplasms (4) · Mouth Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Salivary Gland Neoplasms (2) · Adrenal Gland Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1)
City of Hope Medical Center (4) · M.D. Anderson Cancer Center (4) · University of Washington (3) · Amsterdam UMC, location VUmc (2) · National Cancer Institute (NCI) (2) · Chinese Academy of Medical Sciences (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Nanobiotix (1) · Ohio State University Comprehensive Cancer Center (1) · Radiotherapie (1) · Roswell Park Cancer Institute (1) · Rutgers, The State University of New Jersey (1) · The Netherlands Cancer Institute (1)
United States (24) · Netherlands (2) · Belgium (1) · China (1)
James Welsh (2) · Yvonne M Mowery (2) · A.J. de Langen, MD, PhD (1) · Anurag K Singh (1) · Arya Amini (1) · Christine Fisher, MD (1) · Cristina P. Rodriguez (1) · Cristina Rodriguez (1) · E.F. Smit, MD, PhD (1) · Heike Peulen, MD (1) · Jeffrey Y Wong (1) · Jeremy Brownstein, MD (1) · Joe Chang (1) · Jyoti Malhotra (1) · Kristin Higgins, MD (1)
PMID 31431387, PMID 31996395, PMID 33051340, PMID 33096027, PMID 33720067, PMID 34749885, PMID 37123045, PMID 39384194, PMID 40839922
P30CA033572 (4), UM1CA186690 (2), 2023 (1), P30CA015704 (1), P30CA072720 (1), P30CA093373 (1), P30CA138292 (1), R01CA283603 (1), R01EB027898 (1)